Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Suite 7022, Boston, MA 02115, USA.
Division of Cardiovascular Medicine, University of Miami Hospital, University of Miami Miller School of Medicine, Miami, FL, USA.
Eur Heart J Acute Cardiovasc Care. 2024 Oct 28;13(10):709-714. doi: 10.1093/ehjacc/zuae098.
The Shock Academic Research Consortium (SHARC) recently proposed pragmatic consensus definitions to standardize classification of cardiogenic shock (CS) in registries and clinical trials. We aimed to describe contemporary CS epidemiology using the SHARC definitions in a cardiac intensive care unit (CICU) population.
The Critical Care Cardiology Trials Network (CCCTN) is a multinational research network of advanced CICUs coordinated by the TIMI Study Group (Boston, MA). Cardiogenic shock was defined as a cardiac disorder resulting in SBP < 90 mmHg for ≥30 min [or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain SBP ≥ 90 mmHg] with evidence of hypoperfusion. Primary aetiologic categories included acute myocardial infarction-related CS (AMI-CS), heart failure-related CS (HF-CS), and non-myocardial (secondary) CS. Post-cardiotomy CS was not included. Heart failure-related CS was further subcategorized as de novo vs. acute-on-chronic HF-CS. Patients with both cardiogenic and non-cardiogenic components of shock were classified separately as mixed CS. Of 8974 patients meeting shock criteria (2017-23), 65% had isolated CS and 17% had mixed shock. Among patients with CS (n = 5869), 27% had AMI-CS (65% STEMI), 59% HF-CS (72% acute-on-chronic, 28% de novo), and 14% secondary CS. Patients with AMI-CS and de novo HF-CS were most likely to have had concomitant cardiac arrest (P < 0.001). Patients with AMI-CS and mixed CS were most likely to present in more severe shock stages (SCAI D or E; P < 0.001). Temporary MCS use was highest in AMI-CS (59%). In-hospital mortality was highest in mixed CS (48%), followed by AMI-CS (41%), similar in de novo HF-CS (31%) and secondary CS (31%), and lowest in acute-on-chronic HF-CS (25%; P < 0.001).
SHARC consensus definitions for CS classification can be pragmatically applied in contemporary registries and reveal discrete subpopulations of CS with distinct phenotypes and outcomes that may be relevant to clinical practice and future research.
SHARC(休克学术研究联合会)最近提出了实用共识定义,以规范注册和临床试验中心源性休克(CS)的分类。我们旨在使用 SHARC 定义描述心脏重症监护病房(CICU)人群中的当代 CS 流行病学。
Critical Care Cardiology Trials Network(CCCTN)是由 TIMI 研究组(波士顿,MA)协调的一个多国先进 CICU 研究网络。CS 定义为导致 SBP<90mmHg 持续≥30min 的心脏疾病[或需要使用血管加压药、正性肌力药或机械循环支持(MCS)来维持 SBP≥90mmHg],并伴有灌注不足的证据。主要病因类别包括急性心肌梗死相关 CS(AMI-CS)、心力衰竭相关 CS(HF-CS)和非心肌(继发性)CS。心脏手术后 CS 不包括在内。HF-CS 进一步细分为新发与慢性 HF-CS 急性发作。同时存在心源性和非心源性休克成分的患者单独分类为混合 CS。符合休克标准的 8974 例患者中(2017-23 年),65%为单纯 CS,17%为混合性休克。在 CS 患者(n=5869)中,27%为 AMI-CS(65%为 STEMI),59%为 HF-CS(72%为慢性 HF-CS 急性发作,28%为新发),14%为继发性 CS。AMI-CS 和新发 HF-CS 患者最有可能同时发生心脏骤停(P<0.001)。AMI-CS 和混合 CS 患者最有可能处于更严重的休克阶段(SCAI D 或 E;P<0.001)。AMI-CS 中临时 MCS 使用比例最高(59%)。院内死亡率最高的是混合 CS(48%),其次是 AMI-CS(41%),新发 HF-CS(31%)和继发性 CS(31%)相似,慢性 HF-CS 急性发作(25%)最低(P<0.001)。
CS 分类的 SHARC 共识定义可以在当代注册中实际应用,并揭示具有不同表型和结局的 CS 离散亚群,这些亚群可能与临床实践和未来研究相关。